• News

    Recent news on Salspera

    SALSPERA ANNOUNCES INCREASE in SURVIVAL of STAGE 4 PANCREATIC CANCER PATIENTS TREATED with IMMUNOTHERAPY, SALTIKVA®.
    5 de enero de 2023
    Cambridge, MA (January 5, 2023) - Salspera is announcing positive results from its Phase 2 study...
      FDA GRANTS FAST TRACK DESIGNATION TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
    1 de junio de 2022
    Salspera today announced the U.S. Food and Drug Administration (FDA) granted Fast Track...
      FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
    23 de mayo de 2022
    Salspera today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug...
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More